Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336314 | 0.85 | DRD2 (0.53) | DRD2SLC6A4ADRB2HTR1A | |
| SCHEMBL368353 | 0.84 | CYP2A6 (0.55) | CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL5332205 | 0.83 | DRD2 (0.52) | DRD2SLC6A4SIGMAR1 | |
| SCHEMBL24614167 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL1687607 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL9347724 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL9347774 | 0.82 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL7345698 | 0.82 | CYP2A6 (0.56) | DRD2SLC6A4CYP2A6ADRB2ASIC3 | |
| SCHEMBL346786 | 0.82 | CYP2A6 (0.56) | DRD2SLC6A4CYP2A6ADRB2ASIC3 | |
| SCHEMBL6698397 | 0.76 | SLC6A4 (0.50) | DRD2SLC6A4KDM4ELMNAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | HTR5A, HTR1A, HTR3A | DRD2 84/4885SLC6A4 19/4885KDM4E 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.